NKTR 181

Drug Profile

NKTR 181

Alternative Names: NKTR181

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Nektar Therapeutics
  • Class Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Pain
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Pain
  • Phase II Musculoskeletal pain

Most Recent Events

  • 26 Sep 2016 Pharmacodynamics data from preclinical study in Pain presented at the 16th World Congress on Pain (WCP-2016)
  • 01 Mar 2015 Nektar Therapeutics initiates a phase III trial for Pain (including back pain and non-cancer pain) in USA (NCT02367820)
  • 09 Feb 2015 Nektar Therapeutics plans a phase III trial for Pain in USA (NCT02367820)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top